Prognostic factors and Doxorubicin involved in malignant progression of meningioma

Sci Rep. 2023 Apr 6;13(1):5632. doi: 10.1038/s41598-023-28996-0.

Abstract

Meningioma was the most primary intracranial tumor, but the molecular characteristics and the treatment of malignant meningioma were still unclear. Nine malignant progression-related genes based prognostic signatures were identified by transcriptome analysis between benign meningioma and malignant meningioma. The external dataset GEO136661 and quantitative Real-time Polymerase Chain Reaction were used to verify the prognostic factors. has-miR-3605-5p, hsa-miR-664b-5p, PNRC2, BTBD8, EXTL2, SLFN13, DGKD, NSD2, and BVES were closed with malignant progression. Moreover, Doxorubicin was identified by Connectivity Map website with the differential malignant progression-related genes. CCK-8 assay, Edu assay, wound healing assay, and trans-well experiment were used to reveal that Doxorubicin could inhibit proliferation, migration and invasion of IOMM-Lee Cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Adhesion Molecules
  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Humans
  • Meningeal Neoplasms* / drug therapy
  • Meningeal Neoplasms* / genetics
  • Meningeal Neoplasms* / pathology
  • Meningioma* / drug therapy
  • Meningioma* / genetics
  • Meningioma* / pathology
  • MicroRNAs* / genetics
  • Muscle Proteins
  • Prognosis

Substances

  • MicroRNAs
  • Doxorubicin
  • BVES protein, human
  • Muscle Proteins
  • Cell Adhesion Molecules